appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GlaxoSmithKline Pharmaceuticals Ltd
GLAXO
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.
Brands
Brands
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Glaxosmithkline Pharmaceuticals announces change in senior management
7 hours ago•Business Standard
New product launches may continue to fuel GSK Pharma’s robust growth
1 week ago•Business Standard
GSK Pharma - Business In Recovery Model: Motilal Oswal
1 week ago•Bloomberg Quint
GSK Pharma Q4 Results Review - Sales Growth, Better Operating Leverage Drive Earning: Motilal Oswal
1 month ago•Bloomberg Quint
GSK Pharma Q4 Net Profit Surges 46% To Rs 194.48 Crore
1 month ago•Bloomberg Quint
Recent EventsAll events
Shareholders meeting
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on Jun 28, 2024. Further, the company has informed the Exchange regarding voting results along with copy of scrutinizers report together with copy of minutes. | Download
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on Jun 28, 2024. Further, the company has informed the Exchange regarding voting results along with copy of scrutinizers report together with copy of minutes. | Download
Cash Dividend
Final • Div/Share: ₹ 32
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant